New white paper details key technical milestones and validation of the company's proprietary, capsule-based platform to accelerate breakthroughs across human health BOSTON, Jan. 7, 2026 /PRNewswire/ - ...

Somite is transforming cell therapy by building large-scale foundation models to rapidly accelerate the development of novel cell therapies, significantly compressing timelines and potentially ...

BOSTON, Aug. 20, 2025 /PRNewswire/ -- Somite.ai, a company pioneering foundation models for human stem cells, today announced a strategic investment from AMD Ventures, following Somite's $47M Series A ...

Somite AI is building DeltaStem, a platform and foundation model designed to revolutionize the production of human cells. Cell therapy development company Somite AI has announced the completion of a ...

BOSTON, May 13, 2025 /PRNewswire/ -- Somite AI, a TechBio company leveraging foundation models and proprietary AI to accelerate human cell therapy development, closed its Series A funding round, ...

SMT-M01, a Duchenne muscular dystrophy (DMD) treatment, was granted orphan drug and rare pediatric disease designations by the U.S. Food and Drug Administration (FDA). The cell replacement therapy ...

AI-driven biotech Somite.ai scores dual FDA designations for its novel treatment, potentially fast-tracking hope for families battling this severe genetic disorder. A new drug by TechBio company ...